Jones Day is a leader on 2022 list of "Top Intellectual Property Lawyers" in all major California IP markets
Jones Day is pleased to announce that it is the only firm with attorneys based in each of California's major IP markets—Northern California, Los Angeles, and San Diego—to be recognized on the Daily Journal's list of "Top Intellectual Property Lawyers" for 2022. This is the third consecutive year that the Daily Journal has honored this group of Firm partners, which includes Michael Hendershot, Anthony M. Insogna, Andrea Jeffries, and Randall Kay.
Michael Hendershot, a partner in the Silicon Valley Office who leads the Firm's Northern California IP practice, is a trial lawyer who has focused on patent and trade secret litigation for two decades. He has delivered successful litigation results across the country, including jury wins in the Eastern District of Texas and Delaware. Throughout his career, Mr. Hendershot has advised a range of industry leaders on their most challenging IP matters, such as representing eBay from trial through its landmark Supreme Court victory in eBay v. MercExchange. Judges, clients, and opposing counsel have commended his ability to clearly marshal complex technologies for judges and jurors in a way that is approachable and that reinforces winning case themes, with in-house counsel having described his likability with jurors as "off the charts." He has recently represented Google in a number of patent cases involving a variety of technologies in which he helped obtain transfers, dismissals, and summary judgment, and, in one case, invalidated 177 patent claims. Mr. Hendershot also recently won a patent case for Twilio and has defended Cohesity's innovative data management and storage technology in a range of IP and litigation matters, including a six-patent competitor litigation in the District of Delaware.
Anthony M. Insogna, a partner in the San Diego office, leads the Firm's global Intellectual Property Practice, which comprises more than 220 professionals in 26 cities across seven countries. Mr. Insogna has more than 30 years of experience leading high-stakes patent litigation, global patent strategies, and technology-driven transactions for life sciences companies. He is a trusted advisor to many of the world's leading pharmaceutical and biotech innovators, with extensive experience enforcing and defending patents involving the world's top-selling pharmaceuticals. Mr. Insogna represents Bristol Myers Squibb and Merck & Co. in Abbreviated New Drug Application litigation. He also leads Jones Day teams representing Puma Biotechnology in their Hatch-Waxman and other patent litigation matters around the globe. Mr. Insogna regularly advises companies seeking protection for new technologies, such as revolutionary immuno-oncology drugs, CRISPR-Cas9 (gene editing), gene therapies, and vaccines. He currently leads a team representing ToolGen, a Korean biotech company, in two patent interferences involving CRISPR/Cas9 technology.
Andrea Jeffries is a partner who leads the Firm's Los Angeles IP practice. She is an experienced first-chair IP litigator who leads significant matters involving patents, trade secrets, and other forms of IP across a range of technologies, including pharmaceuticals, medical devices, semiconductors, and wireless communications. Most recently, in the life sciences sector, Ms. Jeffries has represented major pharmaceutical companies in high-stakes patent litigation matters. Ms. Jeffries currently leads the Jones Day team and co-counsel representing Merck Sharp & Dohme Corp. in its ANDA litigation in the District of New Jersey involving Merck's neuromuscular blockade reversal agent BRIDION®, and filled that same role for Merck Sharp & Dohme in a declaratory judgment action in the District of Delaware against Pfizer involving Merck's 15-valent pneumococcal conjugate vaccine, known as Vaxneuvance. The matter was dismissed as a result of a worldwide settlement. Ms. Jeffries also co-led the trial team with co-counsel on behalf of patentee Sloan Kettering Institute and exclusive licensee Juno Therapeutics (a subsidiary of Celgene, a Bristol Myers Squibb company) in a patent infringement matter in the Central District of California involving CAR-T cancer therapy.
Randall E. Kay is a partner in the San Diego Office with more than 30 years of experience as an IP litigator in matters across the country. He predominantly represents IP owners in trade secret, misuse of confidential information, and patent disputes. Mr. Kay has led more than 30 trials and arbitrations in federal and state courts, arbitral forums, and the International Trade Commission involving a wide range of technologies. He also handles IP appeals in federal and state courts. Mr. Kay has particularly deep experience with trade secret disputes involving failed collaborations, employee departures, and data breaches. His trade secret practice often involves complex disputes with international players and events occurring cross-border. Mr. Kay currently leads several global trade secret disputes including two of the first Defend Trade Secrets Act cases filed by U.S.–based companies against foreign actors whose misappropriation took place primarily on foreign soil. He is lead counsel in Micron Technology, Inc.'s international trade secret litigation asserting trade secret and RICO claims against Fujian Jinhua Integrated Circuit Co., Ltd., a Chinese state-owned enterprise. Global news publications reported this civil lawsuit as emblematic of the U.S. trade war with China, as it exemplifies Chinese companies' alleged theft of U.S. intellectual property.